

## Project Disclosure

1. **Client / Project name:** i+solutions / XS2MEDS
2. **Client's website (if available):**
3. **Country:** Kenya and Rwanda
4. **Sector:** Healthcare
5. **Signing date (date of the main transaction document):** 28 September 2023
6. **Total Invest Financing:** We provide a EUR 750,000 repayable development contribution which will bring the project towards the next development phases which will ultimately lead to financial close.
7. **Source of funding:** Impact Accelerator

### 8. Project Description

i+solutions wants to use its expertise to make the XS2Meds solution available to countries in sub-Saharan Africa or other LMIC to provide quality and affordable medicines covering HIV-AIDS, Malaria and TB and include medicine for non-communicable diseases such as diabetes, hypertension, cancer and lung diseases as well as pain treatment and vaccines. This project concerns the first stage of the roll out of the initiative and the preparatory works related to it to test the viability of the initiative.

### 9. Impact / target SDGs

With an initial planned total order size of 500 thousand units across 50 to 75 different products, this project supports the above target by focusing on the import of high-quality medicine covering HIV-AIDS, malaria, tuberculosis and other non-communicable diseases as well as facilitating its last-mile distribution, supporting mainly SDG 3 and indirectly SDG 8.

### 10. ESG Risk category

The proposed development capital will be used for studies, therefore the ESG risk category is C.